Blocking glycolysis abolishes the NK-cells’ ability to control CMV infections, while treatment with the IL-15 super-agonist ALT-803 promotes CMV clearance and even prevents CMV reactivation upon allogeneic SCT34. Here, IL15 is linked to cytomegalovirus infection.